COVID-19 AND COMORBIDITIES

Authors

  • Danijela Loncar Clinic for Internal Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Rahima Jahic Clinic for Infectious Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Humera Porobic-Jahic Clinic for Infectious Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina https://orcid.org/0000-0001-7846-142X
  • Amira Bijedic Clinic for Internal Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Irma Bijedic Clinic for Internal Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Katarina Kovacevic Clinic for Internal Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Asja Omercehajic Clinic for Internal Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Sehveta Mustafic Department of Laboratory Diagnostics, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Alma Ibralic Department of Internal Diseases, Community Health Care Center Živinice, Bosnia and Herzegovina
  • Merima Gegic Department of Microbiology, University Clinical Center Tuzla, Bosnia and Herzegovina
  • Denis Mrsic Clinic for Internal Diseases, University Clinical Center Tuzla, Bosnia and Herzegovina

DOI:

https://doi.org/10.5457/ams.v53i1.664

Keywords:

Covid-19, clinical features, comorbidities

Abstract

Background: The coronavirus disease (Covid 19) is caused by the SARS-CoV-2 virus. The virus has spread globally, causing millions of deaths.

Aim: This study was made with the aim of revealing the clinical features of corona virus infection, as well as assessing the prevalence of comorbidities in patients infected with coronavirus 2 (SARS-CoV-2).

Methods: In this analysis the data was obtained from the hospital information system, involving patients who were treated for Covid-19, in the period January 1 until April 8, 2021.

Results: 400 infected patients were included in the study, 86.2% of whom had comorbidities, and 8.8% without comorbidities. The results showed that the most common clinical symptom is fever in 62%, followed by difficulty breathing in 53%, and cough in 42%. The most prevalent comorbidities were cardiac 68.3%, then endocrinological 33.8%, surgical 16.5%, neurological 15%, oncological 12%, nephrological 11%, and pulmonary 10%. The existence of a significant association between the presence of comorbidities and the patients suffering from COVID-19 on mechanical ventilation due to treatment complications was determined, p=0.000 (p<0.05) at the 95% significance level.

Conclusion: We assessed the prevalence of comorbidities in patients with COVID-19 and found that underlying disease, including cardiac and endocrinological diseases, may be a risk factor for severe forms of the disease.

Key words: Covid-19, clinical features, comorbidities

Downloads

Published

2023-06-20

Issue

Vol. 53 No. 1 (2023)

Section

Original papers

License

Copyright transfer

The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.